Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Do Incretins Play An Important Role In the Cardiovascular System?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Digital Therapeutics Clinical Trials: From Design to Data Interpretation
Engaging Patients and Caregivers About Digital Therapeutics
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Understanding hypertrophic cardiomyopathy and recent guidelines
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?